Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

Question 2

How does nivolumab combined with ILP compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment process look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific side effects I should be aware of with nivolumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion clinical trial (NCT03685890). Contact the study team or your healthcare provider for specific answers.

What this study is about